Apellis Pharmaceuticals Inc
213 articles with Apellis Pharmaceuticals Inc
-
The FDA has one target action date and one advisory committee meeting scheduled for this week. It is also gearing up for an adcomm that could prove to be pivotal for neurodegenerative diseases.
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 6, 2023
3/6/2023
Apellis Pharmaceuticals , Inc. today announced that the company approved the grant of equity awards to 6 new employees with a grant date of March 1, 2023, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2022 Inducement Stock Incentive Plan).
-
Georgia Retina Participates in Apellis Pharmaceuticals’ Groundbreaking Clinical Trials for SYFOVRE, the first and only FDA-approved treatment for Geographic Atrophy
3/1/2023
Georgia Retina is proud to be among the first eyecare practices throughout the country to utilize and participate in Apellis Pharmaceuticals’ groundbreaking clinical trials for SYFOVRE, the first and only FDA-approved treatment for Geographic Atrophy.
-
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences - March 1, 2023
3/1/2023
Apellis Pharmaceuticals, Inc. today announced that the company will participate in the following March investor conferences.
-
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Option to Purchase Additional Shares
2/27/2023
Apellis Pharmaceuticals, Inc. announced the closing of its previously announced underwritten public offering of common stock and pre-funded warrants, including the exercise in full by the underwriters of their option to purchase an additional 833,333 shares.
-
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
2/23/2023
Apellis Pharmaceuticals, Inc. announced the pricing of its underwritten public offering of 3,174,603 shares of its common stock at a public offering price of $63.00 per share.
-
Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
2/22/2023
Apellis Pharmaceuticals, Inc., today announced that it has commenced an underwritten public offering of $300 million of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof).
-
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
2/21/2023
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its fourth quarter and full year 2022 financial results and business highlights.
-
On Friday, the FDA approved Apellis Pharmaceuticals' Syfovre (pegcetacoplan) as the first treatment for geographic atrophy (GA), a leading cause of blindness.
-
FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness
2/17/2023
Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced that the U.S. Food and Drug Administration has approved SYFOVRE™ for the treatment of geographic atrophy secondary to age-related macular degeneration.
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 13, 2023
2/13/2023
Apellis Pharmaceuticals, Inc. announced that the company approved the grant of equity awards to 8 new employees with a grant date of February 1, 2023, as equity inducement awards outside of the company's 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 06, 2023
1/6/2023
Apellis Pharmaceuticals, Inc. announced that the company approved the grant of equity awards to 10 new employees with a grant date of January 3, 2023, as equity inducement awards outside of the company's 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.
-
Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer
1/5/2023
Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced that leading retina specialist Caroline Baumal, M.D., has joined Apellis as chief medical officer.
-
Apellis Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/3/2023
Apellis Pharmaceuticals, Inc. announced that the company will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 9:00 a.m. PT / 12:00 p.m. ET.
-
Apellis Submits Marketing Authorization Application to the European Medicines Agency for Pegcetacoplan for Geographic Atrophy
12/16/2022
Apellis Pharmaceuticals, Inc. today announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency for intravitreal pegcetacoplan, an investigational, targeted C3 therapy, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 07, 2022
12/7/2022
Apellis Pharmaceuticals, Inc. announced that the company approved the grant of equity awards to two new employees with a grant date of December 1, 2022, as equity inducement awards outside of the company's 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.
-
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences - November 22, 2022
11/22/2022
Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced that the company will participate in the following investor conferences.
-
Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)
11/18/2022
Apellis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted Apellis’ unsolicited major amendment to the New Drug Application (NDA) for intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
-
Apellis Pharmaceuticals Reports Third Quarter 2022 Financial Results
11/7/2022
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its third quarter 2022 financial results and business highlights.
-
Apellis is submitting additional 24-month efficacy data to supplement the NDA for its intravitreal candidate pegcetacoplan for GA secondary to AMD.